10:36:34 EST Sun 26 Jan 2020
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Biocure Technology Inc
Symbol CURE
Shares Issued 93,387,632
Close 2018-02-28 C$ 1.02
Recent Sedar Documents

ORIGINAL: Biocure appoints Lichtenwald CFO, director

2018-03-01 02:57 ET - News Release

Received by email:

File: BiocurePRDirectorAppointmentMarch12018FINAL.pdf

March 1st, 2018

FOR IMMEDIATE RELEASE



                    BioCure Announces the Appointment
                        of a New Director and CFO

Vancouver, British Columbia   March 1st, 2018   Biocure Technology Inc. (formerly Gravis Energy Corp.)
(CSE: CURE) (the "Company" or "Biocure") is pleased to announce that effective of today's date, Mr.
Konstatin Lichtenwald will be assuming the role of CFO and has also been appointed as a director of Biocure
Technology Inc.

Ms. Julie Hajduk is resigning from the Board effective immediately. The Board would like to thank Ms.
Hajduk for her tenure with the Company and her efforts with ushering it through the change of business.She
will continue working with the Company on a consulting basis.

Mr, Lichtenwald will be a valued addition to Biocure as he has over ten years of finance and accounting
experience, including corporate compliance, accounting and financial management and IPO, RTO services.
Mr. Lichtenwald offers extensive knowledge and know-how for companies in two key financial jurisdictions,
North America and German speaking parts of Europe. His accounting, financial skills offer a multi-faceted
hands on approach to strategic management and problem solving.

Mr. Lichtenwald specializes in providing corporate finance, valuation, taxation, financial reporting,
consulting and other accounting services to both small businesses as well as public commodity resource
companies. Mr. Lichtenwald also assists in many aspects of clients' administration, financing and other
activities. Mr. Lichtenwald also worked at Ernst & Young GmbH, Germany, in the assurance department.
Mr. Lichtenwald earned his bachelor of business administration degree from Pforzheim University, Germany,
and holds the professional designation of Chartered Professional Accountant (CPA, CGA) and Chartered
Certified Accountant (ACCA), where he is a member of Chartered Professional Accountants of B.C. and
Canada as well as a member of the Association of Chartered Certified Accountants of United Kingdom. Mr.
Lichtenwald has had extensive experience as a controller and CFO of numerous publicly traded and private
corporations in several industries.

Mr. Collin Kim will be stepping down from his role of CFO effective immediately, but will continue to serve
as a director of the Company.

The Company has granted to Mr. Lichtenwald an aggregate of 125,000 options for a two year term at an
exercise price of $1.02 per share with 25,000 options vesting immediately and the balance on March 1, 2019.
 About Biocure

Biocure is a South Korean based Bio Pharmaceutical company specializing in the development and
potential commercialization of biosimilar pharmaceutical products. Biocure is in the process of pre-clinical
trials of five major biosimilar products in South Korea, including Interferon Beta 1b, PEG-Filgrastim and
Ranibizumab as well as CAR-T Cell Therapy. Interferon Beta 1b is used for treating relapsing forms of
multiple sclerosis ("MS") Filgrastim is used to treat neutropenia, a lack of certain white blood cells caused
by bone marrow transplants, chemotherapy, and other conditions. Ranibizumab is used for treating macular
degeneration. It is also used to treat a type of eye problem known as macular edema, as well as certain eye
problems caused by diabetes. Biocure is also developing a foot and mouth disease vaccine, a hair growth
production product and a breast cancer detection kit.

ON BEHALF OF THE BOARD OF DIRECTORS
/s/ "Sang Mok Lee"
     CEO and Director


For further information, please contact:
Biocure Technology Inc. Telephone: 604-609-7149

Certain statements in this news release, which are not historical in nature, constitute "forward looking
statements" within the meaning of that phrase under applicable Canadian securities law. These statements
include, but are not limited to, statements or information concerning the Company's proposed activities
under the Agreement and the expectations of the Company regarding funding payments due pursuant to the
Agreement. These statements reflect management's current assumptions and expectations and by their nature
are subject to certain underlying assumptions, known and unknown risks and uncertainties and other factors
which may cause actual results, performance or events to be materially different from those expressed or implied by
such forward looking statements. Except as required pursuant to applicable securities laws, the Company will not
update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed
information about potential factors that could affect financial results is included in the documents filed from time to
time with the Canadian securities regulatory authorities by the Company. Readers are cautioned not to place undue
reliance on forward looking statements. Neither the Canadian Securities Exchange (the "CSE") nor the Investment
Industry Regulatory Organization of Canada) accepts responsibility for the adequacy or accuracy of this release.
 

File: BiocurePRDirectorAppointmentMarch12018FINAL.DOCX



March 1st, 2018

FOR IMMEDIATE RELEASE  
                          
 
BioCure Announces the Appointment 
of a New Director and CFO


Vancouver, British Columbia - March 1st, 2018 - Biocure Technology Inc. (formerly Gravis Energy Corp.) (CSE: CURE) (the 
--->"Company" or "Biocure") is pleased to announce that effective of today's date, Mr. Konstatin Lichtenwald will be assumin
--->g the role of CFO and has also been appointed as a director of Biocure Technology Inc.

Ms. Julie Hajduk is resigning from the Board effective immediately. The Board would like to thank Ms. Hajduk for her ten
--->ure with the Company and her efforts with ushering it through the change of business.She will continue working with the 
--->Company on a consulting basis. 

Mr, Lichtenwald will be a valued addition to Biocure as he has over ten years of finance and accounting experience, incl
--->uding corporate compliance, accounting and financial management and IPO, RTO services. Mr. Lichtenwald offers extensive 
--->knowledge and know-how for companies in two key financial jurisdictions, North America and German speaking parts of Euro
--->pe. His accounting, financial skills offer a multi-faceted hands on approach to strategic management and problem solving
--->.

Mr. Lichtenwald specializes in providing corporate finance, valuation, taxation, financial reporting, consulting and oth
--->er accounting services to both small businesses as well as public commodity resource companies. Mr. Lichtenwald also ass
--->ists in many aspects of clients' administration, financing and other activities. Mr. Lichtenwald also worked at Ernst & 
--->Young GmbH, Germany, in the assurance department. Mr. Lichtenwald earned his bachelor of business administration degree 
--->from Pforzheim University, Germany, and holds the professional designation of Chartered Professional Accountant (CPA, CG
--->A) and Chartered Certified Accountant (ACCA), where he is a member of Chartered Professional Accountants of B.C. and Can
--->ada as well as a member of the Association of Chartered Certified Accountants of United Kingdom. Mr. Lichtenwald has had
---> extensive experience as a controller and CFO of numerous publicly traded and private corporations in several industries
--->.

Mr. Collin Kim will be stepping down from his role of CFO effective immediately, but will continue to serve as a directo
--->r of the Company. 
 
The Company has granted to Mr. Lichtenwald an aggregate of 125,000 options for a two year term at an exercise price of $
--->1.02 per share with 25,000 options vesting immediately and the balance on March 1, 2019.


About Biocure

Biocure is a South Korean based Bio Pharmaceutical company specializing in the development and potential commercializati
--->on of biosimilar pharmaceutical products. Biocure is in the process of pre-clinical trials of five major biosimilar prod
--->ucts in South Korea, including Interferon Beta 1b, PEG-Filgrastim and Ranibizumab as well as CAR-T Cell Therapy. Interfe
--->ron Beta 1b is used for treating relapsing forms of multiple sclerosis ("MS") Filgrastim is used to treat neutropenia, a
---> lack of certain white blood cells caused by bone marrow transplants, chemotherapy, and other conditions.  Ranibizumab i
--->s used for treating macular degeneration. It is also used to treat a type of eye problem known as macular edema, as well
---> as certain eye problems caused by diabetes. Biocure is also developing a foot and mouth disease vaccine, a hair growth 
--->production product and a breast cancer detection kit. 

ON BEHALF OF THE BOARD OF DIRECTORS
/s/ "Sang Mok Lee"
      CEO and Director


For further information, please contact: 
Biocure Technology Inc. Telephone: 604-609-7149

Certain statements in this news release, which are not historical in nature, constitute "forward looking statements" wit
--->hin the meaning of that phrase under applicable Canadian securities law. These statements include, but are not limited t
--->o, statements or information concerning the Company's proposed activities under the Agreement and the expectations of th
--->e Company regarding funding payments due pursuant to the Agreement. These statements reflect management's current assump
--->tions and expectations and by their nature are subject to certain underlying assumptions, known and unknown risks and un
--->certainties and other factors which may cause actual results, performance or events to be materially different from thos
--->e expressed or implied by such forward looking statements. Except as required pursuant to applicable securities laws, th
--->e Company will not update these forward-looking statements to reflect events or circumstances after the date hereof. Mor
--->e detailed information about potential factors that could affect financial results is included in the documents filed fr
--->om time to time with the Canadian securities regulatory authorities by the Company. Readers are cautioned not to place u
--->ndue reliance on forward looking statements. Neither the Canadian Securities Exchange (the "CSE") nor the Investment Ind
--->ustry Regulatory Organization of Canada) accepts responsibility for the adequacy or accuracy of this release.




© 2020 Canjex Publishing Ltd. All rights reserved.